| 2024-03-27 | +1.98 % |
|
| 2024-03-20 | +0.08 % |
|
| 2024-03-18 | -1.51 % |
|
| 2024-03-15 | +1.02 % |
|
| 2024-03-12 | +0.75 % |
|
| 2024-03-11 | -2.37 % |
|
| 2024-03-08 | -0.57 % |
|
| 2024-03-07 | +1.07 % |
|
| 2024-03-05 | -0.65 % |
|
| 2024-03-04 | -1.83 % |
- The article discusses Revance Therapeutics, Inc.'s proposed public offering of $100 million of its common stock and the intended use of proceeds for commercial growth and other purposes, with Barclays as the book-running manager. The Viatri stock (VTRS) may have gone down due to investor reaction to this offering, along with prevailing market conditions.
- The article discusses Revance Therapeutics, Inc.'s pricing of an underwritten public offering of shares and its intended use of proceeds for commercial growth and other purposes, including advancing its aesthetics portfolio. The Viatris (VTRS) stock may have gone down due to external factors or market conditions, and not directly related to Revance's public offering.
- The article discusses Revance Therapeutics, Inc. announcing the pricing of a $100.0 million public offering of common stock at $6.25 per share, with intended use for advancing commercial growth, supporting product launches, and general corporate purposes, influencing Viataris(VTRS) stock to drop by -1.83% due to factors like economic conditions and uncertainties related to the offering.
|
| 2024-02-28 | -7.11 % |
- Summary: The article provides an overview of the financial market, mentioning factors affecting U.S. economic growth, Federal Reserve's approach to interest rates, approval ratings for President Joe Biden, and global market movements. It notes that Viatris (VTRS) stock experienced a -7.11% decrease, with general market stocks also slipping, while interest rates remained relatively stable and the dollar fluctuated based on easing expectations.
Reason for Viatris (VTRS) stock decline: Viatris' stock decline of -7.11% can be attributed to broader market movements, as global stocks slipped and Wall Street futures were in the red, leading to a negative sentiment in the market impacting Viatris along with other stocks.
- The article discussed stock market futures and the performance of various stocks like eBay, however, it briefly mentioned that Viatris (VTRS) stock was down by -7.11% but did not specifically give a reason for the decline.
- The article discusses various financial updates, focusing on U.S. stock futures, the upcoming earnings reports of companies like Salesforce, TJX Companies, and Viatris, as well as Tesla's announcement about the new Roadster. Viatris stock was down by 7.11% last night, and this decline might be attributed to the upcoming quarterly earnings report from the pharmaceutical group Viatris and general market conditions impacting investor sentiment.
|
| 2024-02-22 | +0.75 % |
|
| 2024-02-21 | +0.15 % |
- The article discusses Shield Therapeutics PLC's expectations for stellar results in 2023, overshadowed by a mistake in previous prescription forecasts, leading to a 49% decrease in shares; however, Viatris Inc's collaboration with Shield for its Accrufer iron deficiency treatment, contributing to increased sales and positive market progress, likely influenced Viatris (VTRS) stock to rise by 0.15%.
- The article discusses Revance Therapeutics, Inc. announcing the release of their fourth quarter and full year 2023 financial results, and hosting a conference call on February 28, 2024, to discuss the results and provide a corporate update. Viatris (VTRS) stock went up based on the partnership between Revance and Viatris to develop a biosimilar to onabotulinumtoxinA for injection, contributing to the positive market performance.
|
| 2024-02-20 | +1.38 % |
|
| 2024-02-15 | +6.21 % |
|
| 2024-02-14 | +0.84 % |
|
| 2024-02-05 | -2.28 % |
|
| 2024-02-02 | -0.17 % |
|
| 2024-02-01 | +0.85 % |
|
| 2024-01-31 | -0.34 % |
|
| 2024-01-30 | -0.59 % |
|
| 2024-01-25 | +0.17 % |
|
| 2024-01-23 | +1.12 % |
|
| 2024-01-18 | -1.66 % |
|
| 2024-01-16 | +0.6 % |
|
| 2024-01-10 | +4.31 % |
|
| 2024-01-08 | -2.25 % |
|
| 2024-01-05 | +3.72 % |
|
| 2024-01-02 | +5.17 % |
|
| 2023-12-28 | +0.74 % |
|
| 2023-12-27 | +0.56 % |
|
| 2023-12-21 | +1.91 % |
|
| 2023-12-18 | -1.66 % |
|
| 2023-12-15 | -1.15 % |
|
| 2023-12-13 | +2.63 % |
|
| 2023-12-11 | |
|
| 2023-12-07 | +0.72 % |
|
| 2023-12-04 | +3.31 % |
|
| 2023-11-30 | +0.55 % |
|
| 2023-11-27 | -0.95 % |
|
| 2023-11-17 | +3.05 % |
|
| 2023-11-15 | +1.52 % |
|
| 2023-11-10 | +1.55 % |
|
| 2023-11-08 | +0.99 % |
|
| 2023-11-07 | -0.87 % |
|
| 2023-11-01 | +0.22 % |
|
| 2023-10-30 | +0.8 % |
|
| 2023-10-26 | +0.22 % |
|
| 2023-10-23 | -4.09 % |
|
| 2023-10-20 | -0.11 % |
|
| 2023-10-19 | -0.64 % |
|
| 2023-10-18 | -0.64 % |
|
| 2023-10-10 | -0.41 % |
|
| 2023-10-04 | +0.52 % |
|
| 2023-10-03 | -3.98 % |
|
| 2023-10-02 | +1.93 % |
|
| 2023-09-28 | +2.29 % |
|